Imacef 1 gm

Description

Imacef 1 gm IM/IV Injection

Indications
Ceftriaxone injection is indicated for the treatment of the following major infections:
Lower respiratory tract infections
Acute Bacterial Otitis Media
Skin and skin structure infections
Urinary tract infections
Gonorrhea
Bacterial Septicemia
Bone and joint infections
Meningitis
Prevention of postoperative infections
Perioperative prophylaxis of infections associated with surgery

Pharmacology
Ceftriaxone is a 3rd generation broad-spectrum parenteral cephalosporin antibiotic. It has potent bactericidal activity
against a wide range of Gram-positive and Gram-negative organisms. Like other cephalosporins and penicillins,
Ceftriaxone kills bacteria by interfering with the synthesis of the bacterial cell wall. Ceftriaxone has a high degree of
stability in the presence of beta lactamases. A remarkable feature of Ceftriaxone is its relatively long plasma
elimination half-life of about 6 to 9 hours, which makes single or once-daily dosage of the drug appropriate for most
patients. Ceftriaxone is not metabolized in the body. About 40-65% of a dose of Ceftriaxone is excreted unchanged in
the urine; the remainder is excreted in the bile and ultimately found in the feces as unchanged drug and
microbiologically inactive compound. The drug is highly protein bound (95%).

Dosage and Administration
Adult: The usual dose is 1 to 2 gm by intravenous or intramuscular administration once a day (or in equally divided
doses twice a day).
Pneumonia, Bronchitis, Acute bacterial otitis media, Skin and skin structure infection, Urinary tract
infections, Bacterial Septicemia, Bone and joint infections, Meningitis: 1 to 2 g IV or IM once a day (or in
equally divided doses twice a day); Maximum dose: 4 gm/day
Uncomplicated gonococcal infections: 250 mg IM as a single dose
Surgical prophylaxis: 1 g IV as a single dose 30 to 120 minutes before surgery
Infants and Children (01 month or older): The usual dose is 50 to 75 mg/kg intravenous or intramuscular
administration once a day (or in equally divided doses twice a day).
Pneumonia, Bronchitis, Skin and skin structure infection, Urinary tract infections, Bacterial Septicemia,
Bone and joint infections: 50 to 75 mg/kg IV or IM once a day (or in equally divided doses twice a day);
Maximum dose: 2 gm/day
Acute bacterial otitis media: 50 mg/kg IM in single dose; Maximum dose: 1 gm/day
Meningitis: 100 mg/kg IV or IM in single daily dose or (or in equally divided doses twice a day); Maximum dose: 4
gm/day
Duration of therapy: Continue for more than 2 days after signs and symptoms of infection have disappeared. Usual
duration is 4 to 14 days; in complicated infections, longer therapy may be required.